Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
CX-2051 led to tumor responses and illness management in sufferers with late-line colorectal most cancers, with a positive security profile.Therapy with the epithelial...
For grownup sufferers with beforehand handled, superior NSCLC with excessive c-Met protein overexpression, the U.S. FDA has authorised therapy with Emrelis.The USA Meals...
